World-leading contract research organization Sygnature Discovery has announced a major new hire to its leadership team, with the appointment of Dr David Witty as Chief Scientific Officer (CSO) to ensure its integrated drug discovery capabilities remain at the cutting edge of the industry.
David will be responsible for ensuring Sygnature Discovery remains globally recognised for the quality of its scientific operations and is able to attract the top scientific talent in the industry.
David is an industry veteran, who started his working life in a medicinal chemistry lab as an 18-…
It can be challenging to hit your milestones and goals when macroeconomic conditions continue to evolve and change. More than ever, you need to optimise your spend, scale up efficiently, maximise productivity, whilst reducing your environmental impact.
At Thermo Fisher Scientific, we provide you with trusted life science solutions that can enable you to get the most from your resources and help bridge gaps so you can meet your milestones quickly.
Discover how we can help you to accelerate your development with innovative life science products and…
This event brought together life science experts and entrepreneurs to explore what should be done to make the UK a scale-up market of choice. The event included a Keynote by George Freeman, MP and a panel discussion, moderated by Lord O’Shaughnessy. The event helped to raise awareness on what factors influence a companies’ decision on where to locate and what policies, investment and other changes can ensure the UK is as attractive and internationally competitive as possible.
Link to full summary: https://www.businessweekly.co.uk/posts/how-can-the-uk-become-the-best-place-to-scale-a-…
Bayland Capital and founding shareholder, CN Innovations Holdings Ltd, to invest $10M and $5.5M, respectively
Investment will expand product development and scaling of the organization to meet increased demand for Organ-on-a-Chip (OOC) solutions
Cambridge, UK, 23 April 2024: CN Bio, a leading provider of single- and multi-organ microphysiological systems, today announced it has raised a $21 million investment in the first close of its Series B fundraising round. The funding has been secured from several new investors; including $10 million from Bayland Capital, and $5.5 million from…
University of Oxford spin-out HydRegen has been revealed as the winner of a programme designed to recognise innovations in planetary health created by Pioneer Group in partnership with CPI.
The 2024 Golden Ticket programme was open to hydrogen and climate technology companies that are innovating solutions to some of the biggest challenges we face, and is backed by funding from the Hydrogen Innovation Initiative (HII) – a trusted group of organisations working with industry, government, and academia to create an investible, globally competitive hydrogen technology and services sector in the UK…
Macomics Unveils its Lead First-in-Class Anti-Pan-LILRB Monoclonal Antibody Programme with Positive Pre-clinical Data Presented at AACR 2024
• Macomics’ lead programme, MACO-355, in IND enabling studies is a ligand-blocking independent pan-LILR monoclonal antibody for the treatment of cancer
• Data presented at AACR 2024 shows MACO-355 is highly potent in macrophage reprogramming under tumour-like immune suppressed conditions
• Data demonstrated Macomics’ ENIGMAC™ platform at-scale CRISPR screening for macrophage target discovery
Edinburgh and Cambridge, UK, 11 April 2024 - Macomics Ltd, a…
Access to compound collection enables greater flexibility and efficiencies in screening and target identification
Cambridge, UK and Kyiv, Ukraine, 11th April 2024: Metrion Biosciences Limited (“Metrion”), the specialist ion channel and cardiac safety screening contract research organisation (CRO) and drug discovery company, and Enamine Ltd (“Enamine”), the global leader in supplying small molecules and early drug discovery services, announced that Metrion has enhanced its High Throughput Screening (HTS) services with the addition of access to Enamine’s compound libraries.
The Enamine compound…
Read April's eNews
Growing Opportunities for our Network, featuring:
✅ Welcome from Tony Jones, CEO, One Nucleus
✅ Review of this year's BLSA (Building Life Science Adventures)
✅ Tony Jones reviews our Inaugural Annual Awards
✅ Boston Bootcamp Winners and What they Can Look Forward To
✅ BIO-Europe Spring - A review of Hot Topics and How to Maximise the Returns and Wellbeing
✅ Prepare for the BIO International Convention in San Diego
✅ Networking Event: Collaboration Opportunities in Puerto Rico for Life Sciences
Regulatory Compliant Tissue Microarrays
AMSBIO reports that its extensive range of FDA tissue microarrays reliably enhances tissue cross-reactivity (TCR) and other target validation studies.
These high-quality tissue microarrays (TMAs) enable high-throughput analysis of a panel of tissue types recognized by the Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
Each TMA features multiple normal tissue types from 3 different donor samples on a single slide to enable simultaneous analysis and facilitate the identification of potential cross-reactive and…
Astex Pharmaceuticals Announce Key Data Presentations at the American Association For Cancer Research (AACR) 2024 Annual Meeting
Cambridge, UK, 3 April 2023 – Astex Pharmaceuticals, a pharmaceutical company based in Cambridge, UK, dedicated to the discovery and development of novel small molecule therapeutics for oncology and diseases of the central nervous system, announced today that it will make five key data presentations at AACR 2024 focusing on its Phase II-ready MDM2 antagonist, ASTX295. AACR 2024 will take place from April 5-10, 2024, at the San Diego Convention Center, San Diego,…